Harumi Takahashi

发表

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study

Yusuke Nakamura, Dan M Roden, Matthew Oetjens, 2013, The Lancet.

Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients.

T. Shiga, Harumi Takahashi, T. Hama, 2019, Journal of cardiology.

CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects

L. Cavallari, S. Patel, M. Perera, 2013, Pharmacogenetics and genomics.

CYP2C9 and Oral Anticoagulation Therapy with Acenocoumarol and Warfarin: Similarities yet Differences

H. Echizen, G. Wilkinson, R. Padrini, 2004, Clinical pharmacology and therapeutics.

Drug interactions between tyrosine kinase inhibitors (gefitinib and erlotinib) and warfarin: Assessment of international normalized ratio elevation characteristics and in vitro CYP2C9 activity

M. Nishio, T. Shiga, Harumi Takahashi, 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Contributions of CYP2C9 and VKORC1 polymorphisms to interindividual difference in maintenance dose of warfarin

Harumi Takahashi, 2006 .

Decreased Warfarin Clearance with the CYP 2 C 9 R 150 H ( * 8 ) Polymorphism

L. Cavallari, S. Patel, Hyunyoung Jeong, 2012 .

A quantitative LC/MSMS method for determination of edoxaban, a Xa inhibitor and its pharmacokinetic application in patients after total knee arthroplasty.

Y. Tsukimura, K. Hanada, Harumi Takahashi, 2018, Biomedical chromatography : BMC.

Effect of low-dose macrolide antibiotics on theophylline disposition in pediatric patients

H. Echizen, Yoshifusa Abe, K. Itabashi, 2007 .

A population approach to eplerenone pharmacokinetics and saturable protein binding.

H. Ogata, Harumi Takahashi, K. Chiba, 2010, Drug metabolism and pharmacokinetics.

Pharmacogenetics of Warfarin Elimination and its Clinical Implications

H. Echizen, H Takahashi, H Echizen, 2001, Clinical pharmacokinetics.

Prediction of the impact of CYP2C9 and VKORC1 genotypes on warfarin-sorafenib interactions in whites and Asians.

Harumi Takahashi, Kazuhiko Asari, 2020, Pharmacogenomics.

Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children

S. Ishikawa, H. Echizen, S. Nomoto, 2000, Clinical pharmacology and therapeutics.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

M. Ritchie, I. Ieiri, H. Echizen, 2006, Pharmacogenetics and genomics.

Determinants of the Over-Anticoagulation Response during Warfarin Initiation Therapy in Asian Patients Based on Population Pharmacokinetic-Pharmacodynamic Analyses

M. Lee, Tsong-Hai Lee, Yuan-Tsong Chen, 2014, PloS one.

Safe use of rocuronium for a post-polio syndrome patient

H. Iida, Harumi Takahashi, K. Tanabe, 2015, Journal of Anesthesia.

Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patients

H. Echizen, G. Wilkinson, Y. Caraco, 2003, Clinical pharmacology and therapeutics.

Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: Report of two cases .

H. Echizen, K. Takeshita, Harumi Takahashi, 2017, International journal of clinical pharmacology and therapeutics.

Correlations between the enantio- and regio-selective metabolisms of warfarin.

M. Lee, Yuan-Tsong Chen, L. Cavallari, 2017, Pharmacogenomics.

5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.

I. Ieiri, H. Echizen, G. Wilkinson, 2004, Blood.

Inter-Individual Differences in Baseline Coagulation Activities and Their Implications for International Normalized Ratio Control During Warfarin Initiation Therapy

Yuan-Tsong Chen, H. Echizen, T. Morita, 2012, Clinical Pharmacokinetics.

A Case of Diffuse Alveolar Hemorrhage Associated with Tegafur Plus Uracil and Warfarin Therapy

Hiroyuki Nakamura, K. Nemoto, S. Oh-Ishi, 2011, Clinical Medicine Insights: Case Reports.

Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance.

H. Echizen, T. Takaba, Harumi Takahashi, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.

T. Shimizu, H. Echizen, S. Nomoto, 1998, Pharmacogenetics.

Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism

L. Cavallari, S. Patel, Hyunyoung Jeong, 2012, Clinical pharmacology and therapeutics.

Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.

L. Cavallari, M. Perera, K. Aquino-Michaels, 2015, Translational research : the journal of laboratory and clinical medicine.

Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.

L. Cavallari, M. Perera, E. Nutescu, 2015, Pharmacogenomics.

Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations

Harumi Takahashi, Ming-Shien Wen, Larisa H. Cavallari, 2019, Clinical Pharmacokinetics.

Population Pharmacokinetic and Pharmacodynamic Analysis of a Class IC Antiarrhythmic, Pilsicainide, in Patients With Cardiac Arrhythmias

Shinichi Kobayashi, H. Echizen, F. Miyake, 2006, Journal of clinical pharmacology.

Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.

K. Yamashita, H. Nakayama, Y. Sasaki, 2010, Japanese journal of clinical oncology.

Clinical and Economic Evaluation of First-line Therapy with FOLFIRI or Modified FOLFOX 6 for Metastatic Colorectal Cancer

K. Yamashita, H. Nakayama, Y. Sasaki, 2010 .

[Translational PK/PD study of the anticoagulant warfarin].

Harumi Takahashi, 2010, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[Pharmacogenetics of warfarin: clinical implications].

Harumi Takahashi, 2010, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms

M. Perera, M. T. Lee, M. G. Scordo, 2016, The Pharmacogenomics Journal.